Charmacy Pharmaceutical Co., Ltd.

SEHK:2289 Voorraadrapport

Marktkapitalisatie: HK$972.0m

Charmacy Pharmaceutical Beheer

Beheer criteriumcontroles 4/4

Charmacy Pharmaceutical's CEO is Chuanglong Yao, appointed in Mar 2000, has a tenure of 24.67 years. total yearly compensation is CN¥728.07K, comprised of 87.4% salary and 12.6% bonuses, including company stock and options. directly owns 31.97% of the company’s shares, worth HK$310.77M. The average tenure of the management team and the board of directors is 2.6 years and 5.7 years respectively.

Belangrijke informatie

Chuanglong Yao

Algemeen directeur

CN¥728.1k

Totale compensatie

Percentage CEO-salaris87.4%
Dienstverband CEO24.7yrs
Eigendom CEO32.0%
Management gemiddelde ambtstermijn2.6yrs
Gemiddelde ambtstermijn bestuur5.7yrs

Recente managementupdates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

Recent updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Apr 24
There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 19
Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Oct 25
These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Sep 17
If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

May 02
Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 15
What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

Feb 17
Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Jan 27
We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Jan 09
Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Dec 22
What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

Nov 29
Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

Analyse CEO-vergoeding

Hoe is Chuanglong Yao's beloning veranderd ten opzichte van Charmacy Pharmaceutical's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

CN¥52m

Mar 31 2024n/an/a

CN¥52m

Dec 31 2023CN¥728kCN¥636k

CN¥51m

Sep 30 2023n/an/a

CN¥74m

Jun 30 2023n/an/a

CN¥96m

Mar 31 2023n/an/a

CN¥93m

Dec 31 2022CN¥732kCN¥638k

CN¥90m

Sep 30 2022n/an/a

CN¥54m

Jun 30 2022n/an/a

CN¥18m

Mar 31 2022n/an/a

CN¥20m

Dec 31 2021CN¥679kCN¥646k

CN¥23m

Sep 30 2021n/an/a

CN¥29m

Jun 30 2021n/an/a

CN¥36m

Mar 31 2021n/an/a

CN¥38m

Dec 31 2020CN¥685kCN¥649k

CN¥41m

Sep 30 2020n/an/a

CN¥35m

Jun 30 2020n/an/a

CN¥29m

Mar 31 2020n/an/a

CN¥34m

Dec 31 2019CN¥714kCN¥650k

CN¥40m

Sep 30 2019n/an/a

CN¥41m

Jun 30 2019n/an/a

CN¥42m

Mar 31 2019n/an/a

CN¥44m

Dec 31 2018CN¥715kCN¥649k

CN¥45m

Sep 30 2018n/an/a

CN¥46m

Jun 30 2018n/an/a

CN¥47m

Mar 31 2018n/an/a

CN¥46m

Dec 31 2017CN¥713kCN¥650k

CN¥45m

Compensatie versus markt: Chuanglong's total compensation ($USD102.24K) is below average for companies of similar size in the Hong Kong market ($USD235.07K).

Compensatie versus inkomsten: Chuanglong's compensation has been consistent with company performance over the past year.

CEO

Chuanglong Yao (54 yo)

24.7yrs

Tenure

CN¥728,071

Compensatie

Mr. Chuanglong Yao has been Chief Executive Officer at Charmacy Pharmaceutical Co., Ltd. since March 2000 and serves as its Vice Chairman since May 31, 2023 and served as its Chairman since May 2015. Mr. Y...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Chuanglong Yao
CEO & Vice Chairman24.7yrsCN¥728.07k31.97%
HK$ 310.8m
Hanzi Zhang
CFO & Executive Director2.6yrsCN¥385.49kgeen gegevens
Yuyan Zheng
VP & Executive Director9.3yrsCN¥991.13kgeen gegevens
Zhijie Lin
Chief Logistics Officer & CTOno dataCN¥188.00kgeen gegevens
Wai Ling Wong
Joint Company Secretary2.6yrsgeen gegevensgeen gegevens
Jiexi Yao
Joint Company Secretary2.6yrsgeen gegevensgeen gegevens

2.6yrs

Gemiddelde duur

45yo

Gemiddelde leeftijd

Ervaren management: 2289's management team is considered experienced (2.6 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Chuanglong Yao
CEO & Vice Chairman24.7yrsCN¥728.07k31.97%
HK$ 310.8m
Hanzi Zhang
CFO & Executive Director2.3yrsCN¥385.49kgeen gegevens
Yuyan Zheng
VP & Executive Director9.5yrsCN¥991.13kgeen gegevens
Chi Wai Wan
Independent Non-Executive Director8.9yrsCN¥144.00kgeen gegevens
Jian Guan
Independent Non-Executive Director8.9yrsCN¥50.00kgeen gegevens
Ling Zhang
Independent Supervisor9.5yrsgeen gegevensgeen gegevens
Xiyue Zheng
Employee Representative Supervisor9.5yrsgeen gegevensgeen gegevens
Hanguo Li
Independent Non-Executive Director1.5yrsCN¥29.30kgeen gegevens
Zheng Fu
Non-Executive Director2.3yrsgeen gegevensgeen gegevens
Jingbin Yan
Non-Executive Chairman2.4yrsgeen gegevensgeen gegevens
Fei Xu
Non-Executive Director1.5yrsgeen gegevensgeen gegevens
Minghong Zhu
Chairman of the Board of Supervisors1.5yrsgeen gegevensgeen gegevens

5.7yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren bestuur: 2289's board of directors are considered experienced (5.7 years average tenure).